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TS-1 is an oral ﬂuoropyrimidine anticancer drug that contains tegafur, gimeracil, and oteracil. A 78-year-
old Japanese male who was diagnosed with carcinoma of the oral ﬂoor (rT4aN0M0) was prescribed
a standard dose of TS-1 (80 mg/day). On Day 8 after administration of TS-1, an eruption developed. There
was erythema, along with vesicles and erosions involving the lip, face, neck, trunk, limbs, and genitals. The
drug-induced lymphocyte stimulation test (DLST) for TS-1 was negative on the 23rd day, but positive on
the 43rd day (20 days after discontinuing prednisolone). The conditionwas diagnosed as StevenseJohnson
syndrome due to TS-1 because of the clinical course and laboratory results. This case and 24 cases pre-
viously reported in the literature were analyzed. The types of drug eruption were drug-related lupus
(9 cases), acral erythema (7 cases), scleroderma-like skin lesion (2 cases), StevenseJohnson syndrome (2
cases), lichenoid eruption (1 case), purpura (1 case), lichen planus (1 case), erythema multiforme (1 case),
hypopigmentation (1 case) and toxic epidermal necrolysis (1 case), respectively. In view of the increasing
usage of TS-1 in several common cancers, clinicians should be aware of drug eruptions due to TS-1.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
TS-1 is an oral ﬂuoropyrimidine anticancer drug that contains
tegafur [a prodrug that cells metabolize to ﬂuorouracil (FU)],
gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which
degrades FU), and oteracil (which inhibits the phosphorylation of
FU in the gastrointestinal tract, thus reducing its side effects on the
gastrointestinal tract).1 We describe the case of a patient who
developed a rare complication of StevenseJohnson syndrome (SJS)
8 days after adjuvant TS-1 administration. To clarify the clinical
characteristics of drug eruption associated with TS-1, this case and
24 previous cases reported in the literature were analyzed.
Case report
A 78-year-old Japanese man who was diagnosed with carcinoma of
the oralﬂoor (rT4aN0M0)was prescribed a standard dose of tegafur/
gimeracil/oteracil (TS-1) at 80 mg/day. On the Day 8 after TS-1
administration, he developed eruptions on his axillae. On the 10th
day, TS-1 was discontinued because of worsening of the conﬂuent
erythema involving the body, blisters on his genitals, and erosions8562, Japan. Tel.: þ81 172 39
awa).
iwanese Dermatological Associatioassociatedwith left eye tearing. Therefore, hewas treatedwith30mg
of prednisolone (PSL). On the 15th day, he developed fever. He also
experienced diarrhea that could not be controlledwith antidiarrheal
medication. On the 18th day, he was referred to our department.
On physical examination, erythema, vesicle formation, and ero-
sions involving the lip, face, neck, trunk, limbs, and genitals were
observed (Figure 1). His laboratory investigation results on admis-
sionwere as follows: white blood cell count, 1.246 109/L; absolute
neutrophil count, 81.7%; eosinophil count, 0%; hemoglobin level,
110 g/L; and platelet count, 232  109/L. Levels of antinuclear anti-
body, ds-DNA, and anti-BP180 antibodywerewithin normal ranges.
Nikolsky’s sign was negative. Ophthalmological evaluation did not
reveal any eye involvement. A skin biopsy specimen taken from his
right thigh showed slight hyperkeratosis, many necrotic keratino-
cytes in the epidermis, subepidermal bulla formation, and vacuolar
degeneration of the basal layer with inﬁltrationsmainly comprising
lymphocytes and eosinophils. In addition, lymphocytes and eosin-
ophils had inﬁltrated the vessels of the superﬁcial dermis (Figure 2).
On the 23rd day, the eruption was improved and therefore we
discontinued oral PSL. The drug-induced lymphocyte stimulation
test (DLST) performed at that point was negative for TS-1 (stimu-
lation index, 162%). On the 43rd day (20 days after discontinuing
PSL), the results of closed patch tests performed using 50%, 25%, and
12.5% TS-1 on the lesional area were negative, but the DLST resultn. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 (AeD) A 78-year-old man with erythema, vesicle formation, and erosions involving the lip, face, neck, trunk, limbs, and genitals.
Figure 2 (A) A skin biopsy specimen showed subepidermal bulla formation and vacuolar degeneration of the basal layer with inﬁltrations mainly comprising lymphocytes and
eosinocytes. (B) Many necrotic keratinocytes were found in the epidermis, and (C) lymphocytes and eosinocytes inﬁltrated the vessels of the superﬁcial dermis.
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Table 1 Review of the drug eruptions due to TS-1.
Patient Sex Age (y) Type of eruption Duration of therapy Examination Reference
1 F 31 Drug-related lupus 21 d Administeredþ ; ANAþ; anti-dseDNAþ 2
7 M 63 Drug-related lupus 10 d 2
8 F 51 Drug-related lupus 3
12 F 48 Drug-related lupus Administeredþ 3
13 M 72 Drug-related lupus 84 d DLST; PT 3
15 M 64 Drug-related lupus 20 d DLST 3
17 M 67 Drug-related lupus 14 d Anti-SSeA/R0þ; DLST; PT 3
22 F 69 Drug-related lupus 4
14 M 62 Drug-related lupus and acral erythema 6 mo Anti-SSeA/R0þ 3
2 M 68 Acral erythema and hyperpigmentation 4 mo DLSTþ; PT; Administeredþ 2
3 M 62 Acral erythema and hyperpigmentation 12 d 2
4 M 73 Acral erythema and hyperpigmentation 17 d Administeredþ 2
18 F 64 Acral erythema and hyperpigmentation 160 d 2
19 M 68 Acral erythema and hyperpigmentation 25 d 2
20 F 47 Acral erythema and hyperpigmentation 28 d 2
5 M 63 Scleroderma-like eruption 16 mo 3
10 M 81 Scleroderma-like eruption 10 d 3
9 F 71 StevenseJohnson syndrome 21 d Administeredþ 3
25 M 78 StevenseJohnson syndrome 8 d DLSTþ; PT Our case
6 M 66 Lichenoid eruption 10 d 2
11 M 74 Purpura 24 d Administeredþ; PT 2
16 M 72 Lichen planus 14 mo 3
21 M 72 Erythema multiforme 8 d 2
23 M 65 Hypopigmentation 6 mo ANAþ 5
24 F 64 Toxic epidermal necrolysis 28 d 1
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as TS-1-associated. SJS was diagnosed on the basis of the clinical
course and laboratory results.
Discussion
A total of 25 cases involving TS-1-associated drug eruptions were
analyzed1e5 (Table 1). Levels of antinuclear antibody were positive
in Cases 1 and 23. The results of patch testswere negative in Cases 2,
11, 13, 17, and our case. The DLST results were positive in Case 2 and
our case, but the results were negative in Cases 13, 15, and 17. The
results of drug challenge testwere positive in Cases 1, 4, 9,11, and 12.
In patients who are suspected to develop allergic reactions, DLST
involving the incorporation of [3H]thymidine ratio into the DNA of
lymphocytes derived from patients, is generally employed for identi-
fyingdrugs that could induceallergy.However,DLSTresultsmayshow
a false-negative response because of steroid, antitumor, and immu-
nosuppressive drugs. Immediately after the onset of drug allergies,
patients are also thought to be more susceptible to false-negative re-
actions. In view of the occurrence of false-negative results, the possi-
bility of drug-induced allergy in patients receiving TS-1 should be
carefullyevaluatedusingacombinationofotherclinical examinations.
Common features of drug-related lupus are as follows: rare
cutaneous manifestations, a high incidence of antihistone anti-
bodies, and reversible symptoms after withdrawal of offending
agents.6 The frequency of discoid lupus erythematosus-like erup-
tion is about 10% among all cases of drug eruptions induced by FU,
based on the statistical report of Fukuda,3 but the ﬁnding is the
proportion of drug-related lupus (9 of 24; 37.5%) in this study. Basal
cells are the target cells most affected by FU agents, because they
are stem cells and are multipotent. Therefore, basal cells damaged
by FU agents seem to be highly susceptible to ultraviolet light (UVL)
irradiation, which induces liquefaction changes and patchy lym-
phocytic inﬁltrations.6 Drug-related lupus by FU agent may be an
excellent model for understanding the pathomechanisms of
development of discoid lesions.6
Bleomycin and cisplatin are known to induce systemic sclerosis-
like reactions in a genetically susceptible host.7 Similarly, toxic ef-
fects or immune systemmodulation by the FUmight be responsible
for systemic sclerosis-like reactions.FU exerts its antitumor effects through several mechanisms,
including inhibition of RNA synthesis and function, inhibition of
thymidylate synthase activity, and incorporation into DNA, leading
to DNA strand breaks.8 When FU is orally administered, extensive
ﬁrst-pass metabolism of FU in the gastrointestinal wall and liver
decreases FU plasma levels and causes severe intestinal mucosal
damage.8 The potent inhibition of dihydropyrimidine dehydroge-
nase by gimeracil present in TS-1 may expose the patient to a high
level of active FU metabolite. This may induce a high incidence of
drug eruption.
To the best of our knowledge, this is the ﬁrst review of the lit-
erature associated with TS-1. In view of the increasing usage of TS-1
in several common cancers, clinicians should be aware of drug
eruptions associated with TS-1 administration.
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